Table 2.
Minimum inhibitory concentrations (MICs) for established antimicrobials as well as sulbactam/durlobactam for representative CRAB isolates from all cases
| Strain | Case1_ACI55 | Case1_ACI59 | Case2_ACI68 | Case3_ACI21 | Case3_ACI41 | Case3_ACI46 | Case3_ACI33 | Case3_ACI31 | Case4_ACI62 | Case5_ACI9 | Case6_ACI73 | Case7_D1 | Env_ sample_ACI4 | Case8_E1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Host | Case1 | Case1 | Case2 | Case3 | Case3 | Case3 | Case3 | Case3 | Case4 | Case5 | Case6 | Case7 | - | Case8 |
| Source | Wound | Resp. | Wound | Wound | Wound | Wound | Wound | Wound | Skin (groin) | Wound | Wound | Wound | Env | Wound |
| MLST (Pasteur) | 2 | 2 | 2 | 1 | 636 | 636 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| MIC (µg/mL) | ||||||||||||||
| Ciprofloxacin | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R |
| Levofloxacin | 8 R | > 8 R | > 8 R | > 8 R | 4 R | 4 R | 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | 8 R |
| Imipenem | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R |
| Meropenem | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R | > 16 R |
| Trimethoprim/sulfamethoxazole | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | 4 I | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | > 8 R | ≤ 1 S |
| Gentamicin‡ | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R |
| Tobramycin‡ | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | 1 S |
| Amikacin‡ | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R | > 32 R |
| Colistin‡ | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S | ≤ 1 S |
| Cefiderocol* | 1 S | .25 S | 1 S | .5 S | 1 S | 1 S | .25 S | .5 S | .5 S | .5 S | .5 S | .5 S | .5 S | 32 R |
| Sulbactam++ | 8 I | 64 R | 64 R | 16 R | 8 I | 8 I | 32 R | 16 R | 32 R | 16 R | 16 R | 16 R | 16 R | 16 R |
| Sulbactam/durlobactam# | 4 S | 4 S | 2 S | 1 S | 1 S | 2 S | 8 I | 4 S | 32 R | 4 S | 4 S | 4 S | 4 S | 4 S |
Breakpoints are according to EUCAST v13.1, unless otherwise stated. Breakpoints for antimicrobials that could be considered for treatment are printed in bold (resp. – respiratory; env. – environmental; MLST – multilocus sequence type)
‡If isolate is reported susceptible, use of antimicrobial can be considered in combination with another effective agent
*CLSI M100Ed33 Breakpoint
++ Based on CLSI M100Ed33 Breakpoint for Ampicillin/sulbactam
#Preliminary CLSI breakpoint: S ≤ 4/4 μg/mL; I 8/4 µg/mL; R ≥ 16/4 μg/mL. Only sulbactam concentration is shown